Alligator Bioscience is a leading brand in the field of developing antibody-based drugs for the treatment of cancer. With a focus on tumor-directed immunotherapy, Alligator Bioscience specializes in the development of agonistic mono- and bispecific antibodies. With global headquarters in Lund, Sweden, the company is actively involved in all stages of drug development, from initial idea to clinical phase 2 studies and beyond.

Alligator Bioscience is listed on Nasdaq Stockholm and is committed to making a significant impact in the fight against cancer. Their innovative products and services are aimed at providing effective and targeted treatment options for patients. With a dedicated team of experts and a strong commitment to research and development, Alligator Bioscience is at the forefront of advancing immunotherapy for cancer treatment.

Their cutting-edge technology platform, Alligator-GOLD®, and other scientific advancements allow them to stay ahead in the field. For more information about Alligator Bioscience and their groundbreaking work, visit their website or get in touch with them via email or phone